After screening for transactivated genes in non-small cell lung cancer (NSCLC) tissue samples, researchers at the University of Tokyo have identified chondrolectin as a potential lung cancer biomarker. In vitro studies suggested a strong association with shorter survival and a link with cancer cell growth and invasive activity. This could be useful as a diagnostic or prognostic biomarker, and as a potential target for drug development. Abstract